Physician profile
Chloe Perate
NPI 1336705664
$6,382.06
in general payments reported to CMS, 2019-2025
43 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2023: $651 · 2024: $2,895 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,943 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,942.50 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,076.86 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $477.52 | 2024-2025 | |
| Astellas Pharma US INC | $398.49 | 2024-2025 | Vyloy, Xospata, Padcev |
| Incyte Corporation | $377.75 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $346.95 | 2023-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $329.93 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $306.01 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.24 | 2023-2025 | |
| Genentech USA, INC. | $226.73 | 2024-2025 | Polivy, Phesgo, Venclexta |
| Janssen Biotech, INC. | $218.10 | 2023-2025 | Erleada, Darzalex, Tecvayli |
| Lilly USA, LLC | $199.26 | 2023-2025 | Verzenio, Retevmo, Jaypirca |
| Adaptive Biotechnologies Corporation | $184.58 | 2021-2024 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $148.39 | 2024-2025 | Ninlaro, Fruzaqla |
| Genmab U.S., INC. | $143.59 | 2023-2025 | Epkinly, Tivdak |
| Amgen INC. | $121.92 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Perate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.